Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2019-03-28 Earnings Release
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
GILEAD EN GALAPAGOS KONDIGEN AAN DAT FILGOTINIB HET BELANGRIJKSTE ONDERZOEKSDOEL HEEFT GEHAALD IN DE FASE 3 FINCH 3-STUDIE BIJ METHOTREXAAT-NAÏEVE REUMAPATIENTEN
Earnings Release Classification · 95% confidence The document is a press release dated March 28, 2019, announcing positive Phase 3 trial results (FINCH 3 study) for the drug filgotinib in rheumatoid arthritis patients. It details efficacy data (ACR scores, remission rates) and safety/tolerability information. This format—a formal announcement of clinical trial results, often including tables and quotes from management, released to the public and regulatory bodies—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a detailed announcement of clinical trial results rather than a full, comprehensive periodic financial report (like a 10-K or IR), and it is not a transcript (CT) or a presentation (IP), the most fitting category is Earnings Release (ER), as these announcements often accompany or precede quarterly financial reporting periods, even if the primary focus here is clinical data. Given the context of a major clinical update, ER is the best fit among the options provided for a significant, time-sensitive corporate announcement of performance/data milestones. Q1 2019
2019-03-28 Dutch
GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND KEY SECONDARY ENDPOINTS IN THE PHASE 3 FINCH 1 RHEUMATOID ARTHRITIS STUDY
Earnings Release Classification · 99% confidence The document is a press release dated March 28, 2019, announcing positive Phase 3 clinical trial results (FINCH 1) for the drug filgotinib in treating rheumatoid arthritis. It details efficacy endpoints (ACR20/50/70, DAS28, HAQ-DI, mTSS) and safety profiles, and includes quotes from management. This format—a formal announcement of key results outside of a mandated periodic report (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical milestones. Since it focuses purely on clinical trial results and does not contain the comprehensive financial statements of a full quarterly report (IR) or annual report (10-K), and it is not a transcript (CT) or a presentation (IP), the most fitting category for a major, immediate results announcement is 'Earnings Release' (ER), as these releases often cover key operational achievements alongside financial figures, or in this case, major clinical achievements that drive future revenue expectations. Given the context of financial reporting databases, major clinical trial readouts are often grouped with ERs or treated as significant operational news. Since 'ER' covers 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a key operational highlight announcement, it fits best here, although 'RNS' (Regulatory Filings) is a close secondary option if the focus was purely regulatory disclosure. However, the structure strongly suggests a proactive announcement of results, aligning with the spirit of an ER. Q1 2019
2019-03-28 English
GILEAD EN GALAPAGOS KONDIGEN AAN DAT FILGOTINIB DE
Earnings Release Classification · 99% confidence The document is a press release, dated March 28, 2019, announcing positive Phase 3 clinical trial results (FINCH 1 study) for the drug filgotinib in treating rheumatoid arthritis. It details efficacy data (ACR scores, DAS28, HAQ-DI, mTSS) and safety profiles, includes quotes from executives, and mentions future presentation at a scientific conference. This format—a detailed announcement of clinical trial results and associated data, often released before a formal regulatory filing or presentation—is characteristic of an Earnings Release (ER) or a general announcement. Since it focuses heavily on clinical trial outcomes and is structured as a formal news announcement from both companies (Gilead and Galapagos), it aligns best with an Earnings Release (ER) which often includes key operational/clinical updates, or potentially an Investor Presentation (IP) if it were a slide deck, but as text, ER is more fitting for a results announcement. However, given the specific focus on clinical trial data release rather than quarterly financial performance highlights, and the mention that detailed results will be submitted for a future conference presentation, this is a scientific/clinical update announcement. In the provided definitions, 'ER' (Earnings Release) is the closest fit for a major periodic announcement of company performance/results, even if the performance metric here is clinical trial success rather than revenue. It is not a full 10-K, AR, or IR. It is a press release announcing key findings, which is the function of an ER. Q1 2019
2019-03-28 Dutch
Galapagos increases share capital through warrant exercises
Capital/Financing Update Classification · 98% confidence The document explicitly announces a capital increase ('kapitaalverhoging') resulting from the exercise of warrants ('uitoefening van warrants'), leading to the issuance of new shares and an increase in the total number of voting rights. This directly relates to changes in the company's capital structure and financing activities. The most appropriate category among the provided definitions is 'Capital/Financing Update' (CAP). It is not an earnings release (ER), an annual report (10-K), or a director's dealing report (DIRS), although management exercised warrants, the primary focus is the capital raise itself.
2019-03-21 Dutch
Galapagos increases share capital through warrant exercises
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces a 'share capital increase arising from warrant exercises' and details the issuance of new ordinary shares and the resulting change in total share capital and voting rights. This directly relates to changes in the company's capital structure and share count. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific corporate action regarding shares.
2019-03-21 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of March 2019. It includes a press release as Exhibit 99.1 dated March 20, 2019. The document is relatively short (2593 characters) and primarily serves as a report submission notice with an attached press release. There is no substantive financial data or detailed report content within the text itself. According to the rules, such filings that mainly provide an announcement or attach a report/press release without containing the full report or detailed financial data should be classified as Regulatory Filings (RNS).
2019-03-21 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.